Cargando…
Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286322/ https://www.ncbi.nlm.nih.gov/pubmed/35634754 http://dx.doi.org/10.1002/clc.23852 |
| _version_ | 1784747984260431872 |
|---|---|
| author | Gao, Linggen Wang, Bin Cheng, Rui |
| author_facet | Gao, Linggen Wang, Bin Cheng, Rui |
| author_sort | Gao, Linggen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9286322 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92863222022-07-19 Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” Gao, Linggen Wang, Bin Cheng, Rui Clin Cardiol Correspondence John Wiley and Sons Inc. 2022-05-30 /pmc/articles/PMC9286322/ /pubmed/35634754 http://dx.doi.org/10.1002/clc.23852 Text en © 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correspondence Gao, Linggen Wang, Bin Cheng, Rui Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” |
| title | Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” |
| title_full | Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” |
| title_fullStr | Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” |
| title_full_unstemmed | Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” |
| title_short | Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” |
| title_sort | reply to comment on “cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta‐analysis” |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286322/ https://www.ncbi.nlm.nih.gov/pubmed/35634754 http://dx.doi.org/10.1002/clc.23852 |
| work_keys_str_mv | AT gaolinggen replytocommentoncardiovascularsafetyoffebuxostatcomparedtoallopurinolforthetreatmentofgoutasystematicandmetaanalysis AT wangbin replytocommentoncardiovascularsafetyoffebuxostatcomparedtoallopurinolforthetreatmentofgoutasystematicandmetaanalysis AT chengrui replytocommentoncardiovascularsafetyoffebuxostatcomparedtoallopurinolforthetreatmentofgoutasystematicandmetaanalysis |